<DOC>
	<DOCNO>NCT02245204</DOCNO>
	<brief_summary>The purpose study : Determining Maximum Tolerated Dose ( MTD ) , Dose-Limiting Toxicity ( DLT ) , pharmacokinetics characteristic , dosage regimen phase II/III Chlorogenic acid injection advance malignant tumor subject ;</brief_summary>
	<brief_title>Tolerance Pharmacokinetic Study Chlorogenic Acid Advanced Cancer</brief_title>
	<detailed_description>1 . Investigate tolerance Chlorogenic acid injection human body , determine Maximum Tolerated Dose ( MTD ) Dose-Limiting Toxicity ( DLT ) Chlorogenic acid injection advance malignant tumor subject ; 2 . Determine human pharmacokinetics characteristic Chlorogenic acid injection ; 3 . Preliminary observation effectiveness effective dose ; 4 . Provide basis dosage regimen phase II/III .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Patients pathologic or/and FNAC confirmation advance cancer without effective treatment treatment failure ; 2 . Between 18 65 year age , KPS≥70 ; 3 . According RECIST 1.1 , patient least one tumor lesion accurately measure CT MRI least one dimension long diameter record ＞2.0cm general CT ＞1.0cm spiral CT ; 4 . Life expectancy least three ( 3 ) month enrollment ; 5 . Patients sufficient baseline organ function whose laboratory data meet follow criterion enrollment : PLT count≥100×10~9/L , WLB count≥4.0×10~9/L ≤12×10~9/L , Neutrophil granulocyte count≥2.0×10~9/L , HGB count≥90g/L , Total bilirubin &lt; =1.5 time ULN , ALT/AST ≤2.5 time ULN , SCr≤1.5 time ULN , Normal ECG LVEF ( ≥50 % ) measure echocardiography ; 6 . Female patient negative pregnant test , male/female patient reproductive age without pregnancy plan next 12 month ; 7 . Volunteered phase 1 trial sign inform consent without protest ; 1 . Patients receive large area radiotherapy （ &gt; 30 % marrow capacity） ; 2 . Patients suffer serious complication , uncontrollable infection , myocardial infarction within past 6 month enrollment , uncontrollable hypertension , thromboembolism etc . ; 3 . Symptomatic patient brain metastasis ( except patient whose brain metastasis control stable status whole brain radiotherapy ) ; 4 . Patients receive therapy chemotherapy within 4 week enrollment ; 5 . Patients used nitrosoureas drug mitomycin within 6 week tyrosine kinase inhibitor within 2 week enrollment ; 6 . Patients receive therapy major surgery within 6 week biopsy surgery within 2 week enrollment ; 7 . Patients receive radical radiotherapy within 6 week local palliative radiotherapy within 2 week enrollment ; 8 . Patients experience grade 2 grade 2 toxicity cause past therapy ; 9 . Patients history drug abuse alcoholism ; 10 . Patients smoke 5 cigarette equivalent tobacco per day ; 11 . Uncontrollable psychopath ; 12 . Pregnant breastfeed woman , patient ( male female ) pregnancy plan ; 13 . Patients receive therapy another investigational drug within 4 week patient still another clinical trial enrollment ; 14 . Known active hepatitis B/hepatitis C , positive HIV/ syphilis antibody ; 15 . Patient need long term treatment cortical hormone immunosuppressive drug visceral organ transplanter ; 16 . Allergic investigational drug ; 17 . Other patient judge ineligible enrollment study investigator ( subinvestigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>